Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 227-561-6 | CAS number: 5888-33-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 4.9 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- other: ECHA REACH guidance R.8, 2012 and ECETOC, 2010
- Overall assessment factor (AF):
- 20.4
- Dose descriptor starting point:
- NOAEL
- Value:
- 100 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 88.2 mg/m³
- Explanation for the modification of the dose descriptor starting point:
Default correction for breathing volume, activity and route-to-route extrapolation according to ECHA R.8, 2012
- AF for dose response relationship:
- 1
- Justification:
- The NOAEL is reliable. No adjustment is required.
- AF for differences in duration of exposure:
- 6
- Justification:
- Default AF 6 for extrapolation from sub-acute to chronic (ECHA 2012)
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- No allometric scaling rat to humans as intraspecies adjustment is accounted for in relative breathing volumes (ECHA R.8, 2012)
- AF for other interspecies differences:
- 1
- Justification:
- Acrylates are metabolised via general metabolic pathways that are common and very similar to rodents and humans and the absence of any specific target organs indicating a specific MOA at high concentrations there is no reason to believe that an additional AF for remaining differences is justified.
- AF for intraspecies differences:
- 3
- Justification:
- Known mode of action involving ubiquitous and non-specific enzyme systems (carboxylesterases) makes a lower variability likely, hence the AF of 3 is sufficiently conservative. (ECETOC, 2010)
- AF for the quality of the whole database:
- 1
- Justification:
- The key studies were of high quality, being rated K1 or K2. No adjustment is required.
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainities. Long-term toxicity data from the metabolites and metabolite donors substances support the conclusion on this hazard level which is based on a screening study.
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.39 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- other: ECHA REACH guidance R.8, 2012 and ECETOC, 2010
- Overall assessment factor (AF):
- 72
- Dose descriptor starting point:
- NOAEL
- Value:
- 100 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 100 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- Default oral to dermal extrapolation with a factor of 1 (ECHA R.8, 2012), in line with consideration on physico-chemical properities and related adsorption potential according to according to ECHA R.7c (2017).
- AF for dose response relationship:
- 1
- Justification:
- The NOAEL is reliable. No adjustment is required
- AF for differences in duration of exposure:
- 6
- Justification:
- Default AF 6 for extrapolation from sub-acute to chronic (ECHA 2012) )
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- Allometric scaling factor rat to humans (ECHA 2012).
- AF for other interspecies differences:
- 1
- Justification:
- Acrylates are metabolised via general metabolic pathways that are common and very similar to rodents and humans and the absence of any specific target organs indicating a specific MOA at high concentrations there is no reason to believe that an additional AF of 2.5 for remaining differences is justified.
- AF for intraspecies differences:
- 3
- Justification:
- Known mode of action involving ubiquitous and non-specific enzyme systems (carboxylesterases) makes a lower variability likely, hence the AF of 3 is sufficiently conservative. (ECETOC, 2010)
- AF for the quality of the whole database:
- 1
- Justification:
- The key studies were of high quality, being rated K1 or K2. No adjustment is required.
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainities. Long-term toxicity data from the metabolites and metabolite donors substances support the conclusion on this hazard level which is based on a screening study.
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- high hazard (no threshold derived)
- Most sensitive endpoint:
- sensitisation (skin)
Acute/short term exposure
- Hazard assessment conclusion:
- high hazard (no threshold derived)
- Most sensitive endpoint:
- sensitisation (skin)
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
Sytemic effects, long term
Calculation from the oral repeated dose/ repro screening study (OECD 422) study with IBOA in rats
DNEL inhal worker long-term
Description |
Value/ factor |
Remark |
|
Step 1) Relevant dose-descriptor |
NOAEL:100 mg/kg bw/d |
NOAEL for urinalysis and reprotoxicity in rats given IBOA by oral gavage in OECD 422 protocol |
|
Step 2) Modification of starting point |
0.38 m³/kg
6.7 m3/10 m3 |
Correction for rat standard breathing volume, 8 hrs (ECHA R.8, 2012) -Correction for activity driven differences of respiratory volumes in workers compared to workers in rest (10 m3/6.7 m3;ECHA R.8, 2012) |
|
Route-to-Route extrapolation |
2 |
Oral to inhalation extrapolation (ECHA R.8, 2012) This is considered as very conservative approach as the low vapour pressure indicates a comparably low absorption potential when compared to oral administration (according to ECHA R.7c, 2017) |
|
NAEC worker |
88.2 mg/m3 |
|
|
Step 3) Assessment factors |
|
|
|
Interspecies |
1 |
No allometric scaling rat to humans as intraspecies adjustment is accounted for in relative breathing volumes (ECHA R.8, 2012) |
|
Intraspecies |
3 |
Known mode of action involving ubiquitous and non-specific enzyme systems (carboxylesterases) makes a lower variability likely, hence the AF of 3 is sufficiently conservative. (ECETOC, 2010) |
|
Exposure duration |
6 |
Default AF 6 for extrapolation from sub-acute to chronic (ECHA 2012) |
|
Dose response |
1 |
The NOAEL is reliable. No adjustment is required. |
|
Quality of database |
1 |
The key studies were of high quality, being rated K1 or K2. No adjustment is required. |
|
Remaining uncertainties |
1 |
No remaining uncertainities. Long-term toxicity data from the metabolites and metabolite donors substances support the conclusion on this hazard level which is based on a screening study. |
|
DNEL |
|
||
Based upon a NOAEL of 100 mg/kg bw/d for rats in an OECD 422 screening study after oral administration |
4,90 mg/m3 |
Using a total factor (POD modifier and AF) of 20.4 (/ 0.38 x 10/6.7 m³ x 2 x 1 x 3 x 6 x 1 x 1 x 1) a DNELlong-term, inhal, workerof 4.90 mg/m³ is derived. |
|
DNEL dermal worker long-term
Description |
Value/ factor |
Remark |
|
Step 1) Relevant dose-descriptor |
NOAEL: 100 mg/kg bw/d |
NOAEL for urinalysis and reprotoxicity in rats given IBOA by oral gavage in OECD 422 protocol |
|
Step 2) Modification of starting point |
1 |
Default oral to dermal extrapolation (ECHA R.8, 2012), in line with consideration on physico-chemical properities and related adsorption potential according to according to ECHA R.7c (2017). |
|
NAEL worker |
100 mg/kg bw/d |
|
|
Step 3) Assessment factors |
|
|
|
Interspecies |
4 |
Allometric scaling rat to humans (ECHA R.8, 2012) |
|
Intraspecies |
3 |
Known mode of action involving ubiquitous and non-specific enzyme systems (carboxylesterases) makes a lower variability likely, hence the AF of 3 is sufficiently conservative. (ECETOC, 2010) |
|
Exposure duration |
6 |
Default AF 6 for extrapolation from sub-acute to chronic (ECHA 2012) |
|
Dose response |
1 |
The NOAEL is reliable. No adjustment is required. |
|
Quality of database |
1 |
The key studies were of high quality, being rated K1 or K2. No adjustment is required. |
|
Remaining uncertainties |
1 |
No remaining uncertainities. Long-term toxicity data from the metabolites and metabolite donors substances support the conclusion on this hazard level which is based on a screening study. |
|
DNEL |
|
||
Based upon a NOAEL of 100 mg/kg bw/d for rats in an OECD 422 screening study after oral administration |
1.39 mg/kg bw/d |
Using a total factor (POD modifier and AF) of 72 (1 x 4 x 3 x 6 x 1 x 1) a DNELlong-term, dermal, workerof 1.39 mg/kg bw/d is derived. |
|
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.45 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- other: ECHA REACH guidance R.8, 2012 and ECETOC, 2010
- Overall assessment factor (AF):
- 69
- Dose descriptor starting point:
- NOAEL
- Value:
- 100 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 43.5 mg/m³
- Explanation for the modification of the dose descriptor starting point:
Default correction for breathing volume and route-to-route extrapolation according to ECHA R.8, 2012
- AF for dose response relationship:
- 1
- Justification:
- The NOAEL is reliable. No adjustment is required.
- AF for differences in duration of exposure:
- 5
- Justification:
- Default AF 6 for extrapolation from sub-acute to chronic (ECHA 2012)
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- No allometric scaling rat to humans as intraspecies adjustment is accounted for in relative breathing volumes (ECHA R.8, 2012)
- AF for other interspecies differences:
- 1
- Justification:
- Acrylates are metabolised via general metabolic pathways that are common and very similar to rodents and humans and the absence of any specific target organs indicating a specific MOA at high concentrations there is no reason to believe that an additional AF for remaining differences is justified.
- AF for intraspecies differences:
- 5
- Justification:
- Known mode of action involving ubiquitous and non-specific enzyme systems (carboxylesterases) makes a lower variability likely, hence the AF of 5 is sufficiently conservative. (ECETOC, 2010)
- AF for the quality of the whole database:
- 1
- Justification:
- The key studies were of high quality, being rated K1 or K2. No adjustment is required.
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainities. Long-term toxicity data from the metabolites and metabolite donors substances support the conclusion on this hazard level which is based on a screening study.
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.83 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- other: ECHA REACH guidance R.8, 2012 and ECETOC, 2010
- Overall assessment factor (AF):
- 120
- Dose descriptor starting point:
- NOAEL
- Value:
- 100 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 100 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- Default oral to dermal extrapolation with a factor of 1 (ECHA R.8, 2012), in line with consideration on physico-chemical properities and related adsorption potential according to according to ECHA R.7c (2017).
- AF for dose response relationship:
- 1
- Justification:
- The NOAEL is reliable. No adjustment is required
- AF for differences in duration of exposure:
- 6
- Justification:
- Default AF 6 for extrapolation from sub-acute to chronic (ECHA 2012)
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- Allometric scaling rat to humans (ECHA R.8, 2012)
- AF for other interspecies differences:
- 1
- Justification:
- Acrylates are metabolised via general metabolic pathways that are common and very similar to rodents and humans and the absence of any specific target organs indicating a specific MOA at high concentrations there is no reason to believe that an additional AF of 2.5 for remaining differences is justified.
- AF for intraspecies differences:
- 5
- Justification:
- Known mode of action involving ubiquitous and non-specific enzyme systems (carboxylesterases) makes a lower variability likely, hence the AF of 5 is sufficiently conservative. (ECETOC, 2010)
- AF for the quality of the whole database:
- 1
- Justification:
- The key studies were of high quality, being rated K1 or K2. No adjustment is required.
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainities. Long-term toxicity data from the metabolites and metabolite donors substances support the conclusion on this hazard level which is based on a screening study.
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- high hazard (no threshold derived)
- Most sensitive endpoint:
- sensitisation (skin)
Acute/short term exposure
- Hazard assessment conclusion:
- high hazard (no threshold derived)
- Most sensitive endpoint:
- sensitisation (skin)
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.83 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- other: ECHA REACH guidance R.8, 2012 and ECETOC, 2010
- Overall assessment factor (AF):
- 120
- Dose descriptor starting point:
- NOAEL
- Value:
- 100 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 100 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- oral study; no adjustment is necessary
- AF for dose response relationship:
- 1
- Justification:
- The NOAEL is reliable. No adjustment is required
- AF for differences in duration of exposure:
- 6
- Justification:
- Default AF 6 for extrapolation from sub-acute to chronic (ECHA 2012)
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- Allometric scaling rat to humans (ECHA R.8, 2012)
- AF for other interspecies differences:
- 1
- Justification:
- Acrylates are metabolised via general metabolic pathways that are common and very similar to rodents and humans and the absence of any specific target organs indicating a specific MOA at high concentrations there is no reason to believe that an additional AF of 2.5 for remaining differences is justified.
- AF for intraspecies differences:
- 5
- Justification:
- Known mode of action involving ubiquitous and non-specific enzyme systems (carboxylesterases) makes a lower variability likely, hence the AF of 5 is sufficiently conservative. (ECETOC, 2010)
- AF for the quality of the whole database:
- 1
- Justification:
- The key studies were of high quality, being rated K1 or K2. No adjustment is required.
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainities. Long-term toxicity data from the metabolites and metabolite donors substances support the conclusion on this hazard level which is based on a screening study.
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
Sytemic effects, long term
Calculation from the oral repeated dose/ repro screening study (OECD 422) study with IBOA in rats
DNEL inhal gen pop long-term
Description |
Value/ factor |
Remark |
|
Step 1) Relevant dose-descriptor |
NOAEL:100 mg/kg bw/d |
NOAEL for urinalysis and reprotoxicity in rats given IBOA by oral gavage in OECD 422 protocol |
|
Step 2) Modification of starting point |
1.15 m³/kg |
Correction for rat standard breathing volume, 24 hrs (ECHA R.8, 2012) |
|
Route-to-Route extrapolation |
2 |
Oral to inhalation extrapolation (ECHA R.8, 2012) This is considered as very conservative approach as the low vapour pressure indicates a comparably low absorption potential when compared to oral administration (according to ECHA R.7c, 2017) |
|
NAEC general population |
43.5 mg/m3 |
|
|
Step 3) Assessment factors |
|
|
|
Interspecies |
1 |
No allometric scaling rat to humans as intraspecies adjustment is accounted for in relative breathing volumes (ECHA R.8, 2012) |
|
Intraspecies |
5 |
Known mode of action involving ubiquitous and non-specific enzyme systems (carboxylesterases) makes a lower variability likely, hence the AF of 5 is sufficiently conservative. (ECETOC, 2010) |
|
Exposure duration |
6 |
Default AF 6 for extrapolation from sub-acute to chronic (ECHA 2012) |
|
Dose response |
1 |
The NOAEL is reliable. No adjustment is required. |
|
Quality of database |
1 |
The key studies were of high quality, being rated K1 or K2. No adjustment is required. |
|
Remaining uncertainties |
1 |
No remaining uncertainities. Long-term toxicity data from the metabolites and metabolite donors substances support the conclusion on this hazard level which is based on a screening study. |
|
DNEL |
|
||
Based upon a NOAEL of 100 mg/kg bw/d for rats in an OECD 422 screening study after oral administration |
1.45 mg/m3 |
Using a total factor (POD modifier and AF) of 69 (/ 1.15 m³ x 2 x 1 x 5 x 6 x 1 x 1 x 1) a DNELlong-term,inhal, gen. pop.of 1.45 mg/m³ is derived. |
|
DNEL dermal general population long-term
Description |
Value/ factor |
Remark |
|
Step 1) Relevant dose-descriptor |
NOAEL:100 mg/kg bw/d |
NOAEL for urinalysis and reprotoxicity in rats given IBOA by oral gavage in OECD 422 protocol |
|
Step 2) Modification of starting point |
1 |
Default oral to dermal extrapolation (ECHA R.8, 2012), in line with consideration on physico-chemical properities and related adsorption potential according to according to ECHA R.7c (2017). |
|
NAEL general population |
100 mg/kg bw/d |
|
|
Step 3) Assessment factors |
|
|
|
Interspecies |
4 |
Allometric scaling rat to humans (ECHA R.8, 2012) |
|
Intraspecies |
5 |
Known mode of action involving ubiquitous and non-specific enzyme systems (carboxylesterases) makes a lower variability likely, hence the AF of 5 is sufficiently conservative. (ECETOC, 2010) |
|
Exposure duration |
6 |
Default AF 6 for extrapolation from sub-acute to chronic (ECHA 2012) |
|
Dose response |
1 |
The NOAEL is reliable. No adjustment is required. |
|
Quality of database |
1 |
The key studies were of high quality, being rated K1 or K2. No adjustment is required. |
|
Remaining uncertainties |
1 |
No remaining uncertainities. Long-term toxicity data from the metabolites and metabolite donors substances support the conclusion on this hazard level which is based on a screening study. |
|
DNEL |
|
||
Based upon a NOAEL of 100 mg/kg bw/d for rats in an OECD 422 screening study after oral administration |
0.83 mg/kg bw/d |
Using a total factor (POD modifier and AF) of 120 (1 x 4 x 5 x 6 x 1 x 1) a DNELlong-term,dermal, gen.pop.of 0.83 mg/kg bw/d is derived. |
|
DNEL oral general population long-term
Description |
Value/ factor |
Remark |
|
Step 1) Relevant dose-descriptor |
NOAEL:100 mg/kg bw/d |
NOAEL for urinalysis and reprotoxicity in rats given IBOA by oral gavage in OECD 422 protocol |
|
Step 2) Modification of starting point |
1 |
No route-to-route extrapolation required. |
|
NAEL general population |
100 mg/kg bw/d |
|
|
Step 3) Assessment factors |
|
|
|
Interspecies |
4 |
Allometric scaling rat to humans (ECHA R.8, 2012) |
|
Intraspecies |
5 |
Known mode of action involving ubiquitous and non-specific enzyme systems (carboxylesterases) makes a lower variability likely, hence the AF of 5 is sufficiently conservative. (ECETOC, 2010) |
|
Exposure duration |
6 |
Default AF 6 for extrapolation from sub-acute to chronic (ECHA 2012) |
|
Dose response |
1 |
The NOAEL is reliable. No adjustment is required. |
|
Quality of database |
1 |
The key studies were of high quality, being rated K1 or K2. No adjustment is required. |
|
Remaining uncertainties |
1 |
No remaining uncertainities. Long-term toxicity data from the metabolites and metabolite donors substances support the conclusion on this hazard level which is based on a screening study. |
|
DNEL |
|
||
Based upon a NOAEL of 100 mg/kg bw/d for rats in an OECD 422 screening study after oral administration |
0.83 mg/kg bw/d |
Using a total factor (POD modifier and AF) of 120 (1 x 4 x 5 x 6 x 1 x 1) a DNELlong-term,dermal, gen.pop.of 0.83 mg/kg bw/d is derived. |
|
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.